UK Markets open in 4 hrs 27 mins

GlaxoSmithKline plc (GLAXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
21.80+0.61 (+2.88%)
At close: 12:12PM EDT
Sign in to post a message.
  • j
    james lovejoy sr
    Repeat previous question ... why was dividend reduced. No indication by GSK.
  • B
    Brewster
    Morningstar comments:
    Buoyed by One-Time Gains, Undervalued Glaxo Posts Strong Q1 With Solid Underlying Core Growth Analyst Note Damien Conover, CFA, Sector Director, 27 Apr 2022

    "GlaxoSmithKline reported strong first-quarter results ahead of our estimates, but we don’t expect any major fair value estimate change based on the outperformance that was aided by several one-time benefits. We view the stock as undervalued, with the market not fully appreciating Glaxo’s growth potential. Also, the upcoming consumer healthcare divestment (called Haleon) in mid-2022 holds potential to create value. Relative to comparable market valuations (but lacking all the financial data needed for our traditional discounted cash flow analysis), Haleon’s valuation could be close to GBP 50 billion, which would imply solid valuation expansion potential for the remaining Glaxo business. We believe Haleon’s brand power holds potential to support a moat, and intangible assets (largely patents) should support Glaxo’s wide moat following the Haleon divestment. In the quarter, total sales increased 32%, but one-time benefits (sales of COVID-19 treatment Xevudy and inventory stocking) likely added over 20% growth. However, the underlying core growth looks solid and should be sustainable over the next five years, driven by shingles vaccine Shingrix and new HIV drugs for long-acting treatment and prevention. Shingrix looks on track to exceed management's longterm guidance of GBP 4 billion by 2026 based on leading efficacy and limited competition. As the COVID-19 vaccines begin to take less priority due to market saturation (especially in developed markets), we expect a strong ramp in Shingrix sales but likely slower than the over 100% growth seen in the first quarter (helped by inventory buildup). On key pipeline events, we highlight phase 3 readouts, with adult RSV vaccine data expected in the second quarter and otilimab in rheumatoid arthritis in late 2022. The potential 2023 approval of daprodustat for anemia could hold blockbuster potential. However, we view these assets with a higher level of uncertainty given the heavy competitive dynamics in each of these markets".
  • e
    eduardo
    New acquisition by GSK was done at an awesome price of 1.9B real worth value well over 3.4B using fourth grade simple math. (projected sales 1B just the first year )
  • v
    vincento
    why was the quarterly dividend reduced for July 2022 distribution? TIA
  • C
    Clifford
    New high , and 5% yield . Why go anywhere else ?
  • G
    G
    GSK is one to be a big LONG in ...recession and stagflation proof!!!
  • J
    Johnfod
    Anyone know if GSK's slide is due to the overall stock market's recent decline or some weakness in GSK? Seems disconcerting that the shares are dropping daily. Please share your thinking.
  • R
    Rex
    What an absolutely GLORIOUS stock!
  • T
    TBone
    FDA pulls approval from GSK's COVID treatment and the stock goes UP? Kinda reverse logic, IMO.
  • e
    eduardo
    46,64 $ and is not even June. As we get closer to the spin off-price rise faster in my opinion.
  • R
    Russell
    Where are all the Emma bashers now?
  • A
    Ali
    cheapest stock ever with perfect div
  • e
    eduardo
    So if you thought this stock was going to stay at 42 for another 20y let me tell you that you are completely clueless. Find another hobby.
  • e
    eduardo
    From googling the web found this:

    "Do spinoffs still outperform?
    The findings that followed were that spinoffs outperformed the S&P 500 by 10% per year, with the S&P realizing an average annual return of 10%, the spinoffs averaged 20% per year."
  • a
    arthur
    Maybe a good time to revisit AUPH and get the company on the cheap . With GSK sales team this lupus drug could be a huge revenue source.
  • R
    Rex
    Beautiful yield
  • P
    Pat
    Note to GSK: Acquire Agen while the price is affordable

    GSK will need the QS-21 stimulon in the 25(+) p3 & p4 studies.
  • G
    G
    where is my newCo split???? Emma needs to go....
  • B
    Brewster
    Morningstar Positive:
    GlaxoSmithKline's Upcoming Divestment of Consumer Group
    Haleon Holds Potential to Unlock Value
    Analyst Note Damien Conover, CFA, Sector Director, 28 Feb 2022

    "Following GlaxoSmithKline’s capital markets day on consumer segment Haleon, we are not making any
    major changes to our fair value estimate. We continue to view Glaxo as undervalued, as the market is
    likely not ascribing enough value to the consumer segment and the strong core drug and vaccine group.
    While the consumer segment’s brand power largely drives the moat in the consumer healthcare
    segment, we believe the intangible assets largely with patents will enable the remaining GlaxoSmithKline to retain its wide moat following the divestment of Haleon in midsummer.

    Glaxo laid out expectations for 4%-6% annual growth for Haleon over the medium term, which is higher
    than our 3% annual expectations. However, Haleon’s strong group of power brands and focus on
    incremental research and development advancements should make management’s guidance
    achievable.

    Given the high expectations in the consumer healthcare industry, we expect Haleon to trade at a higher
    valuation multiple than the drug industry. Relative to comparable market valuations (and lacking all the
    financial data needed for our traditional discounted cash flow valuation), Haleon’s valuation could be
    close to GBP 50 billion. This valuation is supported by Glaxo’s recent decision to reject Unilever’s GBP 50
    billion bid for Haleon, citing too low of a valuation. However, tax concerns may have also factored into
    the rejection decision. If Haleon achieves a valuation close to GBP 50 billion, then the remaining drug and vaccine unit (new GlaxoSmithKline) will trade with a relatively low valuation, which we think is underappreciated by the market. A valuation close to drug companies with comparable growth suggests strong upside in the new GlaxoSmithKline. Also, Haleon will pay the new GlaxoSmithKline a special dividend of more than GBP 7 billion before the divestment, creating more optionality with the remaining company to make tuck-in acquisitions to drive faster growth".
  • P
    Pat
    GSK: WHY NOT JUST ACQUIRE AGENUS ALREADY?

    Most notable and biggest UK companies in the world based on their popularity and market cap.

    GSK has $5.86B in free cash flow in 2021 and $5.9B Cash & Short Term Investments

    Most notable and biggest UK companies in the world based on their popularity and market cap.

    15. Reckitt Benckiser Group plc (OTC: RBGPF)
    14. London Stock Exchange Group plc (Frankfurt: LS4C.F)
    12. RELX PLC (NYSE: RELX)
    11. Anglo American plc (Swiss: AAM.SW)
    10. Aon plc (NYSE: AON)
    9. BP p.l.c. (NYSE: BP)
    8. British American Tobacco p.l.c. (NYSE: BTI)
    7. GlaxoSmithKline plc (NYSE: GSK)
    No deal for GSK consumer health: Unilever stops raising $68B bid amid investor pushback. The $68 billion price “fundamentally undervalued” the consumer business.
    The drugmaker said it’s on track to separately list the consumer arm, which owns brands including Panadol painkillers and Sensodyne toothpaste, in mid-2022.
    Ranking 7th on our list of most valuable UK companies in the world, GlaxoSmithKline plc (NYSE: GSK) focuses on creating, discovering, developing, manufacturing, and marketing pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and other international markets. Founded in 1715 and located in Brentford, the United Kingdom, GlaxoSmithKline plc (NYSE: GSK) provides pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
    6. HSBC Holdings plc (NYSE: HSBC)
    5. Diageo plc (NYSE: DEO)
    4. Rio Tinto Group (NYSE: RIO)
    3. Unilever PLC (NYSE: UL)
    Inaugurated in 1894 and based in London, the United Kingdom, Unilever PLC (NYSE: UL) offers ice cream, mayonnaise, soups, ketchups, bouillons, seasonings, and tea categories under the Ben & Jerry’s, Magnum, Breyers, Brooke Bond, Knorr, Heart (Wall’s), Hellmann’s, Lipton, The Vegetarian Butcher, and Unilever Food Solutions brands. Securing the 3rd spot on our list of most valuable UK companies in the world, Unilever PLC (NYSE: UL) formed its identity through the sales of fast-moving consumer goods in Asia, Africa, the Middle East, Turkey, Russia, Ukraine, Belarus, the Americas, and Europe.
    2. Linde plc (NYSE: LIN)
    1. AstraZeneca PLC (NASDAQ: AZN)

    https://finance.yahoo.com/news/15-most-valuable-uk-companies-210645851.html
    In this article, we will discuss the 15 most valuable UK companies in the world. You can skip our detailed analysis of these companies, and go directly to 5 Most Valuable UK Companies in the World. According to McKinsey’s Facing the future: Britain’s
    In this article, we will discuss the 15 most valuable UK companies in the world. You can skip our detailed analysis of these companies, and go directly to 5 Most Valuable UK Companies in the World. According to McKinsey’s Facing the future: Britain’s
    finance.yahoo.com